Latest News
- November 29, 2022
In a new paper, Pramod Mistry and colleagues describe a thriving program that provides therapies to people with rare diseases.
- November 28, 2022
The American College of Neuropsychopharmacology (ACNP) will award Kristen J. Brennand, PhD, its 2022 Daniel H. Efron Research Award for outstanding basic research contributions to neuropsychopharmacology.
- October 21, 2022
Most families with autosomal dominant polycystic kidney disease (ADPKD) possess a genetic mutation in PKD1, that impacts the protein polycystin-1 (PC1). In a new article published online Friday, October 21, 2022, in the Journal of the American Society of Nephrology, a Yale team led by Stefan Somlo, MD and Sorin Fedeles, PhD, MBA demonstrated that the activation of the transcription factor XBP1 in vivo can improve the residual function of a mutant form of PC1, thereby decreasing the severity of ADPKD.
- October 20, 2022
Stem cell-derived neurons from combat veterans with and without post-traumatic stress disorder (PTSD) provide insights into how genetics can make someone more susceptible to developing PTSD following trauma exposure, according to a study conducted by scientists from several research institutions, including Yale School of Medicine.
- October 07, 2022Source: YaleNews
Brennand's research integrates expertise in genetics, neuroscience, and stem cells to identify the mechanisms that underlie brain disease,
- September 22, 2022Source: Yale New Haven Health
Arya Mani, MD, FACC, FAHA, director of the Yale Medicine Cardiovascular Genetics Program, says certain cardiovascular diseases are significantly impacted by genes.
- September 22, 2022
Yale School of Medicine's Ob/Gyn Chair Hugh Taylor, MD, was a leader of a clinical trial for a drug that could sharply advance uterine fibroid treatment.
- September 15, 2022
Renato Polimanti, PhD, assistant professor of psychiatry at Yale School of Medicine, has received a 3-year grant from the National Institute of Mental Health (NIMH) to evaluate the association of internalizing disorders with the risk, onset, and vulnerability of COVID-19.
- September 13, 2022
The use of AI to analyze complex datasets presents a groundbreaking opportunity to answer questions previously beyond the reach of biomedical researchers. The Bridge2AI program will support the creation of accessible, AI-ready datasets that can be used multiple times for a range of medical challenges.